Primary resistance against integrase strand transfer inhibitors in integrase strand transfer inhibitor-naive patients failing first- and second-line ART in Tanzania

Dolutegravir Resistance in Malawi’s National HIV Treatment Program

(2022) Joep J van Oosterhout et al.   Open Forum Infectious Diseases

Pre-treatment integrase inhibitor resistance is uncommon in ART-naïve individuals with HIV-1 subtype A1 and D infections in Uganda

(2021) Suzanne M. Mccluskey et al.   AIDS

Predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine

(2021) Amy G. Cutrell et al.   AIDS

Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations

(2021) Sello Given Mikasi et al.   BMC INFECTIOUS DISEASES

Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia

(2021) Yared Belete Belay et al.   Pharmacoeconomics-Open

HIV-1 Genetic Diversity and Natural Polymorphisms of the Integrase Gene in Integrase Inhibitor-Naive Patients in Harare, Zimbabwe

(2021) Amanda Madyadi et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in North-Western Tanzania

(2021) Shimba Henerico et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Circulating HIV-1 integrase genotypes in Tanzania: Implication on the introduction of Integrase Inhibitors-based ART regimen

(2020) Salim Masoud et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy

(2020) Kairoonisha Mahomed et al.   SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE

Prevalence of integrase strand transfer inhibitor resistance mutations in antiretroviral-naive HIV-1-infected individuals in Cameroon

(2020) Benjamin M Wenk et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial

(2020) Willem D F Venter et al.   Lancet HIV

Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon

(2020) Alexandra Calmy et al.   Lancet HIV

Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens

(2019) Seth C Inzaule et al.   LANCET INFECTIOUS DISEASES

Pre-treatment and acquired HIV drug resistance in Dar es Salaam, Tanzania in the era of tenofovir and routine viral load monitoring

(2019) Godfrey Barabona et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

HIV-1 Integrase Diversity and Resistance-Associated Mutations and Polymorphisms Among Integrase Strand Transfer Inhibitor-Naive HIV-1 Patients from Cameroon

(2019) Sello Given Mikasi et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Four class drug resistant HIV-1 subtype C in a treatment experienced individual on dolutegravir based antiretroviral therapy in Botswana

(2018) Kaelo K. Seatla et al.   AIDS

Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda

(2018) Emmanuel Ndashimye et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

MEGA X: Molecular Evolutionary Genetics Analysis across Computing Platforms

(2018) Sudhir Kumar et al.   MOLECULAR BIOLOGY AND EVOLUTION

Analyses of HIV-1 integrase sequences prior to South African national HIV-treatment program and availability of integrase inhibitors in Cape Town, South Africa

(2018) Dominik Brado et al.   Scientific Reports

Rapid Development of High Level Resistance to Dolutegravir with Emergence of T97A Mutation in Two Treatment Experienced Individuals with Baseline Partial Sensitivity to Dolutegravir

(2018) Jomy M George et al.   Open Forum Infectious Diseases

Key Factors Influencing the Emergence of Human Immunodeficiency Virus Drug Resistance in Low- and Middle-Income Countries

(2017) Carole L Wallis et al.   JOURNAL OF INFECTIOUS DISEASES

Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome

(2017) Michael E. Abram et al.   PLoS One

Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors

(2017) Isabelle Malet et al.   mBio

HIV Drug Resistance Among Children Initiating First-Line Antiretroviral Treatment in Uganda

(2016) Cissy Kityo et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

HIV virological failure and drug resistance in a cohort of Tanzanian HIV-infected adults

(2016) Claudia Hawkins et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance

(2015) Atsuko Hachiya et al.   ANTIVIRAL RESEARCH

Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: Performance evaluation of the new REGA version 3 and seven other tools

(2013) Andrea-Clemencia Pineda-Peña et al.   INFECTION GENETICS AND EVOLUTION

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

(2013) Sharon L. Walmsley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patterns of HIV-1 Drug Resistance After First-Line Antiretroviral Therapy (ART) Failure in 6 Sub-Saharan African Countries: Implications for Second-Line ART Strategies

(2012) R. L. Hamers et al.   CLINICAL INFECTIOUS DISEASES

A ‘missing’ family of classical orthogonal polynomials

(2011) Luc Vinet et al.   Journal of Physics A-Mathematical and Theoretical

Development of Antiretroviral Drug Resistance

(2011) Mark A. Wainberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

HIV Drug Resistance (HIVDR) in Antiretroviral Therapy-Naïve Patients in Tanzania Not Eligible for WHO Threshold HIVDR Survey Is Dramatically High

(2011) Christa Kasang et al.   PLoS One